APR-246

 

Topic mentions per year

Topic mentions per year

2010-2018
024620102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Two main causes of platinum resistance are mutation in the tumor suppressor gene TP53 and drug-induced increase in intracellular… (More)
Is this relevant?
2015
2015
OBJECTIVES p53 is a critical tumour suppressor and is mutated in 70% of oesophageal adenocarcinomas (OACs), resulting in… (More)
Is this relevant?
2013
2013
Targeting p53 by the small-molecule PRIMA-1(Met)/APR-246 has shown promising preclinical activity in various cancer types… (More)
Is this relevant?
2013
2013
The low-molecular-weight compound APR-246 (PRIMA-1MET) restores wild-type conformation and function to mutant p53, and triggers… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Background:Though p53 mutations are rare in ES, there is a strong indication that p53 mutant tumours form a particularly bad… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE APR-246 (PRIMA-1MET) is a novel drug that restores transcriptional activity of unfolded wild-type or mutant p53. The main… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2011
2011
PURPOSE Small cell lung cancer (SCLC) is a highly malignant disease with poor prognosis, necessitating the need to develop new… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
BACKGROUND APR-246 belongs to a new generation of the compounds that restore normal p53 function in cells with mutated or wild… (More)
Is this relevant?
2011
2011
Disseminating malignant melanoma is a lethal disease highly resistant to radio- and chemotherapy. Therefore, the development of… (More)
Is this relevant?
2010
2010
The low molecular weight compound PRIMA-1 and the structural analog PRIMA-1MET, also named APR-246, reactivate mutant p53 through… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?